Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Interim Report January-March 2025, is as of today, available on the Company's website, FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted ...

with UCB’s Cimzia (certolizumab) and AbbVie’s Humira (adalimumab). “We think we have a very efficacious product, we showed a very positive safety profile, we have two weeks administration ...

Vimpat is UCB’s second-biggest drug after TNF inhibitor Cimzia (certolizumab pegol) which is also due to lose patent protection by 2024 and contributed €622 million out of total sales of €2. ...

In addition, UCB has recently gained approval for certolizumab pegol (Cimzia) for the treatment of RA with a dosing regimen of administration once every 4 weeks (which amounts to one more dose per ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

At close: April 28 at 12:00:49 PM GMT+1 ...